RxDoctor Payments Data

Jason Empson

Nurse Practitioner · Coos Bay, ORNPI 1770255283

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (34.9%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Urogen Pharma, Inc. at 45.0% of the total. Reporting peaked in 2023 at $1,629 and has fallen 91.5% since, to $138 in 2025. Among nurse practitioner clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,916in general payments, 2019–2025

Across 31 payments — averaging $61.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Urogen Pharma, Inc.$862
  • Teleflex LLC$716
  • Tolmar, Inc.$68
  • Astellas Pharma US Inc$65
  • AbbVie$39
  • Bayer$33
  • plus $132 from 7 others

What the payments were for

  • Speaking & faculty fees$62533%
  • Travel & lodging$66835%
  • Food & beverage$62333%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,916 in reported general payments places this provider in the 95th percentile of 997 nurse practitioner providers in Oregon.

See all nurse practitioner providers in Oregon

Medicare billing

Part B allowed, 2024
$149,816
Medicare patients
867
Services billed
7,044

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron117$76,510
GemtesaVibegron40$32,647
Tamsulosin Hcl622$14,305
Potassium Citrate ErPotassium Citrate14$6,356
Testosterone Cypionate81$3,126
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst116$2,877
Finasteride182$2,363
Oxybutynin Chloride117$2,120
Dutasteride38$1,784
Methenamine Hippurate11$1,669
Terazosin Hcl50$1,411
Oxybutynin Chloride ErOxybutynin Chloride53$1,337
CefuroximeCefuroxime Axetil70$1,105
Solifenacin Succinate31$1,074
Estradiol23$1,036

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$65$76,510117 claims
Sumitomo Pharma America, Inc.Gemtesa$15$32,64740 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 997 nurse practitioner providers in Oregon.

Other nurse practitioner in Coos Bay

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →